Company Description
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders.
Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression.
In addition, the company’s Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain.
The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy.
Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
| Country | Canada |
| Founded | 1996 |
| IPO Date | Nov 5, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 370 |
| CEO | Ian Mortimer |
Contact Details
Address: 200-3650 Gilmore Way Burnaby, BC V5G 4W8 Canada | |
| Phone | 604 484 3300 |
| Website | xenon-pharma.com |
Stock Details
| Ticker Symbol | XENE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001582313 |
| CUSIP Number | 98420N105 |
| ISIN Number | CA98420N1050 |
| Employer ID | 98-0661854 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Ian C. Mortimer C.M.A., CPA, M.B.A. | President, Chief Executive Officer and Director |
| Thomas Patrick Kelly J.D. | Chief Financial Officer |
| Andrea DiFabio J.D. | Chief Legal Officer and Corporate Secretary |
| Dr. Christopher John Kenney M.D. | Chief Medical Officer |
| Darren S. Cline M.B.A. | Chief Commercial Officer |
| Dr. Matthew D. Ronsheim Ph.D. | Chief Operating Officer |
| Shelley McCloskey B.A. | Executive Vice President of Human Resources |
| Dr. Robin P. Sherrington Ph.D. | Executive Vice President of Strategy and Innovation |
| Dr. James R. Empfield Ph.D. | Executive Vice President of Drug Discovery |
| Colleen Alabiso | Senior Vice President of Corporate Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 5, 2026 | 144 | Filing |
| Jun 5, 2026 | 144 | Filing |
| Jun 3, 2026 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jun 3, 2026 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jun 3, 2026 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jun 3, 2026 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jun 3, 2026 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jun 3, 2026 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jun 3, 2026 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jun 3, 2026 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |